Alliancebernstein L.P. Grows Stake in Hims & Hers Health, Inc. $HIMS

Alliancebernstein L.P. boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 10.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 812,123 shares of the company's stock after buying an additional 78,756 shares during the quarter. Alliancebernstein L.P. owned approximately 0.36% of Hims & Hers Health worth $23,998,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HIMS. Northern Trust Corp raised its holdings in shares of Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock valued at $71,969,000 after acquiring an additional 397,310 shares during the last quarter. Yong Rong HK Asset Management Ltd increased its position in shares of Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock worth $70,920,000 after purchasing an additional 700,100 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Hims & Hers Health during the first quarter worth approximately $58,403,000. Two Sigma Investments LP raised its stake in Hims & Hers Health by 37.9% in the 4th quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company's stock valued at $47,571,000 after purchasing an additional 540,274 shares during the last quarter. Finally, BIT Capital GmbH lifted its holdings in Hims & Hers Health by 7.4% in the 1st quarter. BIT Capital GmbH now owns 1,642,493 shares of the company's stock valued at $48,536,000 after purchasing an additional 112,949 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $47.67 on Wednesday. The firm has a 50 day simple moving average of $50.03 and a 200-day simple moving average of $45.12. The stock has a market cap of $10.77 billion, a price-to-earnings ratio of 59.59, a price-to-earnings-growth ratio of 3.35 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. Hims & Hers Health, Inc. has a 1-year low of $13.84 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company's revenue was up 72.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a report on Monday, June 23rd. Morgan Stanley restated an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Finally, Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Reduce" and a consensus price target of $38.92.

Insiders Place Their Bets

In related news, insider Patrick Harrison Carroll sold 60,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the sale, the insider directly owned 169,940 shares of the company's stock, valued at approximately $9,105,385.20. This trade represents a 26.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the company's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at $112,023,016.02. The trade was a 22.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,384,728 shares of company stock valued at $71,149,098. 17.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.